転移・再発乳癌に対するベバシズマブとパクリタキセル併用療法(JO19901)の安全性に関する検討

Takayuki Ueno(The Cancer Institute Hospital), Shigemitsu Takashima(National Cancer Center), Koji Oda(Tokyo Metropolitan University), Shunji Kamigaki, Fujiwara Yasuhiro, Ito Yoshinori, Ono Shinji, Kenjiro Aogi(Hiroshima University), Hiroji Iwata(Aichi Cancer Center), Masahiro Kashiwaba(Iwate Medical University), Masuda Shinzo

日本癌治療学会誌

January 1, 2011

Cited by 0

Related Papers

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

|The Lancet Oncology|2016|1.8k

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

|The Lancet|2020|1.8k

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

|New England Journal of Medicine|2015|1.6k

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

|New England Journal of Medicine|2018|1.3k

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

|The Lancet|2020|1.1k